Cardiomyocytes for Mechanistic Cardiovascular Safety Liabilities

Cardiovascular safety liabilities remain an important concern in drug development that impacts candidate attrition and may lead to adverse clinical events. These liabilities (as evidenced by various oncology drugs) span the spectrum of arrhythmias, contractile dysfunction, myocardial injury and infl
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news